Skip to content

A clinical study to evaluate the efficacy of Navanga Kwath with Vitamin E in the management of Non-Alcoholic Fatty Liver Disease(Yakritroga)

A randomized open-labelled comparative clinical study to evaluate the efficacy of Navanga Kwath with Vitamin E in the management of Non-Alcoholic Fatty Liver Disease(Yakritroga) - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/070820
Enrollment
60
Registered
2024-07-18
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

None listed

Sponsors

INSTITUTE FOR AYURVED STUDIES AND RESEARCH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. The patient presented with cardinal features of Yakritroga as described in Ayurvedic texts. 2. Randomly selected irrespective of their caste, religion and sex. 3. Patient with the age group of age of 25-60 years. 4. Voluntary agreement & and enrolment to participate in the study. 5. The ratio of AST/ALT below 2. 6. Non-alcoholic Fatty Liver Disease patient who was diagnosed by abdomen ultrasonic examination and non-drinker or total abstainer or with alcohol intake of less than 20 gm per day for females and less than 30 gm per day for males. 7. NAFLD confirmed by USG with or without having symptoms like fatigue and mild discomfort in the upper quadrant of the abdomen. 8. Both freshly detected & and previously diagnosed cases of NAFLD.

Exclusion criteria

Exclusion criteria: 1 Patient below 25 years and above 60 years of age 2 The ratio of AST or ALT over 2 3 Metabolic syndromes such as Type I and II Diabetes Mellitus Hypertension Cerebrovascular Accident Myocardial Infarction and Chronic Kidney Disease 4 Any dysfunction of the liver besides Non Alcoholic Fatty Liver Diseases like Viral Hepatitis Liver Parenchymal Disease Ascites portal Hypertension Hepato Cellular Carcinoma Auto Immune Hepatitis Primary Biliary Cirrhosis Wilsons Disease and liver Transplantation or any other conditions interfering with the result of the treatment of non alcoholic fatty liver disease patient 5. Prior treatment with any medicine that affects the treatment of Non Alcoholic Fatty Liver Disease within 3 months 6 Patient suffering from HIV TB other infectious diseases Malignancies Major Psychiatric Problems or any other serious problems 7. Patient on prolonged (more than 6 weeks) medication with corticosteroids antidepressants anti cholinergic hepatotoxic medicines or any other drug that may influence the outcome of The study 8 Alcoholics and any other drug abusers 9 Pregnant and Lactating women 10 The patient has a history of Hypersensitivity to the trial drug or any of its ingredients

Design outcomes

Primary

MeasureTime frame
Reduction in scoring pattern of sign and symptoms such as Tastelessness, Indigestion, Mild pain in the upper abdomen, Feeling of heaviness, Diminution of the agni, Feeling of nausea and vomiting, FatigueTimepoint: 42 days

Secondary

MeasureTime frame
Improvement in haematological parameters such as Serum cholestrol, Serum trigylcerides, SGPT, SGOT, Alkaline PhosphataseTimepoint: 70 days

Countries

India

Contacts

Public ContactDr. Divya

Institute for Ayurved studies and research SKAU Kurukshetra

drlamba.neha@gmail.com9736333868

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026